Cargando…

Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer

PURPOSE: Non-small-cell lung cancer (NSCLC) has a large worldwide prevalence with a high mortality rate. Chemotherapy has offered modest improvements in survival over the past two decades. Immune checkpoint modulation with programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibition has...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iafolla, Marco A. J., Juergens, Rosalyn A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2017
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5382272/ https://www.ncbi.nlm.nih.gov/pubmed/28428947 http://dx.doi.org/10.3389/fonc.2017.00067

Ejemplares similares

The Interplay Between Programmed Death Ligand 1 and Vimentin in Advanced Non-Small-Cell Lung Cancer
por: Bronte, Giuseppe, et al.
Publicado: (2021)

Efficacy and Feasibility of Programmed Death-1/Programmed Death Ligand-1 Blockade Therapy in Non-Small Cell Lung Cancer Patients With High Antinuclear Antibody Titers
por: Mouri, Atsuto, et al.
Publicado: (2021)

Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis
por: Zhang, Chen, et al.
Publicado: (2021)

Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
por: Yu, Wei-Bo, et al.
Publicado: (2019)

Analysis of Real‐World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death‐1 and Programmed Cell Death‐Ligand 1 Inhibitors in Advanced Non‐Small Cell Lung Cancers
por: Ayers, Kristin L., et al.
Publicado: (2021)

Incidence of Immune-Related Adverse Events with Program Death Receptor-1- and Program Death Receptor-1 Ligand-Directed Therapies in Genitourinary Cancers
por: Maughan, Benjamin L., et al.
Publicado: (2017)

The Efficacy and Safety of Programmed Death-1 and Programmed Death Ligand 1 Inhibitors for the Treatment of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
por: He, Shukang, et al.
Publicado: (2021)

Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors
por: Song, Joon Seon, et al.
Publicado: (2019)

Improving the synergistic combination of programmed death‐1/programmed death ligand‐1 blockade and radiotherapy by targeting the hypoxic tumour microenvironment
por: Mudassar, Faiqa, et al.
Publicado: (2022)

p53 Expression, Programmed Death Ligand 1, and Risk Factors in Urinary Tract Small Cell Carcinoma
por: Golijanin, Borivoj, et al.
Publicado: (2021)

Prolonged Response of Metastatic Programmed Death-Ligand 1 (PD-L1) Negative Basaloid Squamous Cell Carcinoma of the Lung to Maintenance Immunotherapy
por: Fox, Ashley D, et al.
Publicado: (2022)

The predictive role of soluble programmed death ligand 1 in digestive system cancers
por: Ruan, Jian, et al.
Publicado: (2023)

Inhibition of Programmed Death Receptor-1/Programmed Death Ligand-1 Interactions by Ginsenoside Metabolites
por: Yim, Nam-Hui, et al.
Publicado: (2020)

Granulomatosis With Polyangiitis in a Patient on Programmed Death-1 Inhibitor for Advanced Non-small-cell Lung Cancer
por: Sibille, Anne, et al.
Publicado: (2019)

Long-Term Real-World Outcomes of First-Line Pembrolizumab Monotherapy for Metastatic Non-Small Cell Lung Cancer With ≥50% Expression of Programmed Cell Death-Ligand 1
por: Velcheti, Vamsidhar, et al.
Publicado: (2022)

Prognostic and Clinicopathological Value of Programmed Cell Death Ligand1 Expression in Patients With Small Cell Lung Cancer: A Meta-Analysis
por: Cai, Huarong, et al.
Publicado: (2020)

Prognostic Role of Soluble Programmed Death Ligand 1 in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Liao, Guixiang, et al.
Publicado: (2021)

Safety and Activity of Programmed Cell Death 1 Versus Programmed Cell Death Ligand 1 Inhibitors for Platinum-Resistant Urothelial Cancer: A Meta-Analysis of Published Clinical Trials
por: Li, Zaishang, et al.
Publicado: (2021)

The Prognostic Value of Circulating Soluble Programmed Death Ligand-1 in Cancers: A Meta-Analysis
por: Huang, Pei, et al.
Publicado: (2021)

Prognostic Value of Galectin-9 Relates to Programmed Death-Ligand 1 in Patients With Multiple Myeloma
por: Lee, Byung-Hyun, et al.
Publicado: (2021)

Correlation Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Programmed Death-Ligand 1 Expression as Prognostic Markers in Non-Small Cell Lung Cancer
por: Pirlog, Cristina-Florina, et al.
Publicado: (2022)

The Clinical Significance of Soluble Programmed Cell Death-Ligand 1 (sPD-L1) in Patients With Gliomas
por: Liu, Shujun, et al.
Publicado: (2020)

The Impact of Programmed Death-Ligand 1 Expression on the Prognosis of Early Stage Resected Non-Small Cell Lung Cancer: A Meta-Analysis of Literatures
por: Shi, Tao, et al.
Publicado: (2021)

Terphenyl-Based Small-Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein–Protein Interaction
por: Muszak, Damian, et al.
Publicado: (2021)

The Degree of Programmed Death-Ligand 1 (PD-L1) Positivity as a Determinant of Outcomes in Metastatic Triple-Negative Breast Cancer Treated With First-Line Immune Checkpoint Inhibitors
por: Di Spazio, Lorenzo, et al.
Publicado: (2022)

Association Between Programmed Death-Ligand 1 Expression and the Vascular Endothelial Growth Factor Pathway in Angiosarcoma
por: Bagaria, Sanjay P., et al.
Publicado: (2018)

Programmed Cell Death Protein 1/Programmed Cell Death Protein Ligand 1 Immunosuppressants in Advanced Non-Small Cell Lung Cancer Research Progress in Treatment
por: Li, Feng, et al.
Publicado: (2022)

Programmed death‐ligand 1 expression in swine chronic infections and enhancement of interleukin‐2 production via programmed death‐1/programmed death‐ligand 1 blockade
por: Ganbaatar, Otgontuya, et al.
Publicado: (2021)

Checkpoint inhibition through small molecule-induced internalization of programmed death-ligand 1
por: Park, Jang-June, et al.
Publicado: (2021)

The potential of soluble programmed death-ligand 1 (sPD-L1) as a diagnosis marker for colorectal cancer
por: Shao, Weifang, et al.
Publicado: (2022)

Soluble programmed cell death protein-1 and programmed cell death ligand-1 in sepsis
por: Banerjee, Debasree, et al.
Publicado: (2018)

Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism
por: Jaafar, Jaafar, et al.
Publicado: (2018)

Expression of Programmed Death-Ligand 1 and Programmed Death-1 in Patients with Extramammary Paget's Disease
por: Goto, Hiroyuki, et al.
Publicado: (2021)

Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma
por: Nie, Run-Cong, et al.
Publicado: (2020)

Lymphocyte activation gene-3 is associated with programmed death-ligand 1 and programmed cell death protein 1 in small cell lung cancer
por: Sun, Hui, et al.
Publicado: (2021)

Expression patterns of programmed death-1 and programmed death-1 ligand-1 on T cells in gastric cancer
por: Kim, Ji-Hyun, et al.
Publicado: (2019)

The Prognostic Value of Programmed Death-Ligand 1 in a Chinese Cohort With Clear Cell Renal Cell Carcinoma
por: Xiao, Wen-jun, et al.
Publicado: (2019)

Programmed Death Ligand 2 Gene Polymorphisms Are Associated With Lung Adenocarcinoma Risk in Female Never-Smokers
por: Liang, Sheng-Kai, et al.
Publicado: (2021)

Efficacy and Safety of Programmed Death-1/Programmed Death-Ligand 1 Inhibitor for Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis
por: Liao, Pei-Fei, et al.
Publicado: (2023)

Effect of Gamma Knife Radiosurgery and Programmed Cell Death 1 Receptor Antagonists on Metastatic Melanoma
por: Nordmann, Nathan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_guqr6g1hf3ctae4ki0tiq68qgk